@article{445dbbfa0c694789ab70d6bdf23e0a20,
title = "Response to letter re: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression",
author = "Nobuaki Ochi and Eiki Ichihara and Nagio Takigawa and Daijiro Harada and Koji Inoue and Takuo Shibayama and Shinobu Hosokawa and Daizo Kishino and Shingo Harita and Naohiro Oda and Naofumi Hara and Katsuyuki Hotta and Yoshinobu Maeda and Katsuyuki Kiura",
note = "Funding Information: EI received honoraria from Boehringer Ingelheim and additional research funding from MSD. NT received honoraria and research funds from Eli Lilly Japan, AstraZeneca, Daiichi-Sankyo, Chugai Pharmaceutical, Taiho Pharmaceutical, Pfizer, Boehringer-Ingelheim, and Ono Pharmaceutical. TN received honoraria from MSD, Bristol-Myers Squibb and Eisai. TN received research funds from Kyowa Hakko Kirin, Nippon Kayaku, Takeda Pharmaceutical and Astellas Pharma. DH received research funds from Eli Lilly, MSD, Chugai, Pfizer, BMS, AstraZeneca, Novartis, Kissei and Takeda, honoraria from MSD, ONO pharmaceutical, BMS, Kyowa Hakko Kirin, AstraZeneca, Boehringer Ingelheim and Lilly. SH received honoraria from Bristol–Myers Squibb and MSD. TS received research funding from ONO pharmaceutical and Shionogi pharmaceutical. KH received honoraria from Taiho Pharmaceutical and Chugai Pharmaceutical. KH received additional research funding from MSD and Chugai Pharmaceutical. YM received honoraria from Chugai Pharmaceutical and Bristol–Myers Squibb. KK received honoraria from Chugai Pharmaceuticals.",
year = "2021",
month = nov,
doi = "10.1016/j.ejca.2021.07.044",
language = "English",
volume = "157",
pages = "523--524",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
}
